Vivian Liu

Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA.

Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. Its products focuses in six main categories, including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. The company was founded on January 15, 1959 and is headquartered in Englewood, CO.

Founded in 1996 by Todd Wyche, Brinson Patrick Securities Corp. is an SEC-registered broker/dealer located in New York City. The firm works exclusively with issuers to raise equity capital with little or no impact to stock price, and with a very high level of service and expertise, through their DOCS (Dynamic Offering of Common Stock) at-the-market financing facility.

Part of OxOnc Development LP, Oxonc Services Co LLC is a company that develops pharmaceutical products. The company is based in Princeton, NJ.

OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands.

ThermoGenesis Corp. engages in the provision of medical laboratories services. The company is headquartered in Rancho Cordova, CA.

FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs including drugs to treat liver cancer and autoimmune diseases. Their lead product, PrevOnco, is a H+/K+-ATPase inhibitor, which was granted Orphan Drug Status by the FDA in August 2008. PrevOnco is currently in Phase 3 development as a potential second line therapy for patients with liver cancer. They also have an innovative pipeline of novel products for the Over-the Counter markets including Apeaz and Regia, indicated for pain relief and bleeding of the gums, respectively.